News
Watch
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Management of Beta-Thalassemia

Management of Beta-Thalassemia

Episodes

Specialty:

All

Year:

All

EP. 1: Overview of Beta Thalassemia

January 31st 2020

EP. 2: Prevalence and Clinical Presentation of B-Thalassemia

January 31st 2020

EP. 3: β-Thalassemia Severity and Impact on Patients

January 31st 2020

EP. 4: Impact of β-Thalassemia on the Providers

January 31st 2020

EP. 5: Current Approaches for Beta-Thalassemia

January 31st 2020

EP. 6: The Role of Transfusion for Beta-Thalassemia

January 31st 2020

EP. 7: Understanding Transfusion for Beta-Thalassemia

January 31st 2020

EP. 8: Iron Dysregulation & Allogeneic Stem Cell Transplantation

January 31st 2020

EP. 9: Approval of Novel Therapy for Beta-Thalassemia

January 31st 2020

EP. 10: End Points of Phase III Study for Beta-Thalassemia

January 31st 2020

EP. 11: Future Impact of the Novel Therapy for Beta-Thalassemia

January 31st 2020

EP. 12: The Potential for Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 13: The Process for Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 14: The Cost and Safety of Gene Therapy in Beta-Thalassemia

January 31st 2020

EP. 15: Pipeline Agents for the Treatment of Beta-Thalassemia

January 31st 2020

EP. 16: Final Thoughts on the Treatment of Beta-Thalassemia

January 31st 2020

Trending on OncLive

Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC

FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap

Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC

Colorectal Cancer Isn't the Only Gastrointestinal Cancer Rising in Young Adults

Long-Term Follow-Up Confirms Tivozanib Monotherapy Efficacy in 2L/3L mRCC